CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) Polymorphisms and Bladder Cancer Risk in a Turkish Population |
Berber, Ufuk
(Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy)
Yilmaz, Ismail (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) Yilmaz, Omer (Urology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) Haholu, Aptullah (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) Kucukodaci, Zafer (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) Ates, Ferhat (Urology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) Demirel, Dilaver (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) |
1 | Feng Z, Hu W, Rom WN, Beland FA, Tang MS (2002). 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis, 23, 1721-7. DOI ScienceOn |
2 | Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res, 60, 3440-4. |
3 | Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H (1992). Point-mutational MspI and IleVal polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev, 1, 485-9. |
4 | Ji YN, Wang Q, Suo LJ (2012). CYP1A1 polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: A meta-analysis. PLoS ONE, 7, 43397. DOI |
5 | Lee KM, Kang D, Clapper ML, et al (2008). CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among asian populations. Cancer Epidemiol Biomarkers Prev, 17, 1120-6. DOI ScienceOn |
6 | Lopez-beltran A, Cheng L, Mazzucchelli R, et al (2008). Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res, 28, 2893-900. |
7 | Pollard C, Smith SC, Theodorescu D (2010). Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med, 12, 10. DOI ScienceOn |
8 | Rebbeck TR, Walker AH, Jaffe JM, et al (1999). Glutathione S-transferase- (GSTM1) and - (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev, 8, 283-7. |
9 | Salinas-Sanchez AS, Donate-Moreno MJ, Lopez-Garrido MP, Gimenez-Bachs JM, Escribano J (2012). Role of CYP1B1 gene polymorphisms in bladder cancer cusceptibility. J Urol, 187, 700-6. DOI ScienceOn |
10 | Senthilkumar KP, Thirumurugan R (2012). GSTM1 and GSTT1 allele frequencies among various Indian and non-Indian ethnic groups. Asian Pac J Cancer Prev, 13, 6263-7. 과학기술학회마을 DOI ScienceOn |
11 | Sharma A, Pandey A, Sardana S, et al (2012). Genetic polymorphisms of GSTM1 and GSTT1 genes in Delhi and comparison with other Indian and global populations. Asian Pac J Cancer Prev, 13, 5647-52. 과학기술학회마을 DOI ScienceOn |
12 | Shukla D, Dinesh KA, Hallikerimath S, Vivekanandhan S, Venkatakanthaiah Y (2012). Genetic polymorphism of drug metabolizing enzymes (GSTM1 and CYP1A1) as risk factors for oral premalignant lesions and oral cancer. Biomedical Papers, 156, 253-9. DOI ScienceOn |
13 | Song DK, Xing DL, Zhang LR, et al (2009). Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in central China. Cancer Detection and Prev, 32, 416-23. DOI ScienceOn |
14 | Tanaka Y, Sasaki M, Kaneuchi M, et al (2002). Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun, 296, 820-6. DOI ScienceOn |
15 | Toruner GA, Akyerli C, Ucar A, et al (2001). Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in Turkish population. Arch Toxicol, 75, 459-64. |
16 | Turesky RJ, Le Marchand L (2011). Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol, 24, 1169-214. DOI ScienceOn |
17 | Yang CX, Matsuo K, Wang ZM, Tajima K (2005). Phase I/II enzyme gene polymorphisms and esophageal cancer risk: A meta-analysis of the literature. World J Gastroenterol, 11, 2531-8. DOI |
18 | Aktas D, Hascicek M, Sozen S, et al (2004). CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Gene Cytogenet, 154, 81-5. DOI ScienceOn |
19 | Zhou LP, Luan H, Dong XH, et al (2012). Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 3165-72. 과학기술학회마을 DOI ScienceOn |
20 | Aktas D, Guney I, Alikasifoglu M, et al (2002). CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol, 86, 124-8. DOI ScienceOn |
21 | Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66. DOI |
22 | Atinkaya C, Taspinar M, Sakiragaoglu S, et al (2012). The effect of CYP1A1, GSTT1 and GSTM1 polymorphisms on the risk of lung cancer: a case-control study. Hum Exp Toxicol, 31, 1074-80. DOI ScienceOn |
23 | Bartsch H, Nair U, Risch A, et al (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 9, 3-28. |
24 | Boffetta P, Jourenkova N, Gustavsson P (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8, 444-72. DOI ScienceOn |
25 | Botelho MC, Machado JC, da Costa JMC (2010). Schistosoma haematobium and bladder cancer. What lies beneath? Virulence, 1, 84-7. DOI ScienceOn |
26 | Cengiz M, Ozaydin A, Ozkilic AC, Dedekarginoglu G (2007). The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients. Int Urol Nephrol, 39, 1043-8. DOI |
27 | Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36. DOI ScienceOn |
28 | Fatima M, Garcia N, Munoz X, et al (2010). Simultaneous genotyping of GSTT1 and GSTM1 null polymorphisms by melting curve analysis in presence of SYBR Green I. J Mol Diagn, 12, 300-4. DOI ScienceOn |